Core Viewpoint - Company’s wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has participated in the 11th national centralized drug procurement organized by the National Joint Procurement Office, with some products expected to be selected for this procurement [1][2]. Group 1: Product Information - The products proposed for selection include Ephedrine Hydrochloride Injection and Meprobamate Injection, which received drug registration certificates from the National Medical Products Administration in March 2023 and August 2024, respectively [2]. - The final prices and supply provinces for the selected products will be based on the data released by the Joint Procurement Office [1]. Group 2: Impact on the Company - The sales revenue from the proposed selected products currently accounts for a small proportion of the company's total revenue, and it is expected that there will be no significant impact on the company's performance in the short term [2]. - If the company successfully signs procurement contracts and implements them, it will enhance the accessibility of the products and improve the company's brand influence [2].

Group 1 - Core viewpoint: Yifan Pharmaceutical announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected, including adrenaline hydrochloride injection [1] - Revenue composition for the first half of 2025: Pharmaceuticals accounted for 85.53%, pharmaceutical raw materials and intermediates 11.47%, and high molecular materials 3.0% [1] - Current market capitalization of Yifan Pharmaceutical is 16 billion yuan [1]

Core Viewpoint - Yifan Pharmaceutical (002019) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected for this procurement [1] Group 1 - Yifan Pharmaceutical's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., is involved in the bidding process for the centralized procurement [1] - The products involved in the bidding include Adrenaline Hydrochloride Injection and Meprobamate Injection, which are intended to be selected in this round of procurement [1]

Core Insights - The latest round of national centralized drug procurement in China has successfully awarded contracts for 55 drugs, with 453 products from 272 companies qualifying for selection, expanding the total number of covered drugs to 490 [1] Group 1: Company Participation - Kelun Pharmaceutical and Yuandong Biological, two listed pharmaceutical companies from Chengdu, announced a total of 14 products that are likely to be selected in the recent procurement round [1] - Kelun Pharmaceutical reported that it and its subsidiaries participated in the 11th national drug procurement, with 12 products likely to be selected across various treatment areas including liver disease, oncology, and mental health [3][4] Group 2: Product Details - The 12 products from Kelun Pharmaceutical cover a range of diseases, including chronic liver disease, ovarian cancer, depression, and chronic obstructive pulmonary disease, showcasing the company's diverse product portfolio [3] - The proposed winning prices for Kelun's products vary significantly, from 2.11 yuan per bag for a specific injection to 195.37 yuan per box for an oncology drug, indicating a wide range of medication price points [3] Group 3: Financial Impact - For the 12 products proposed for selection by Kelun, most had zero sales revenue prior to this procurement, with only a few products generating minimal revenue in 2023 or 2024 [3] - Yuandong Biological announced that its selected products, including a specific injection and a tablet, contributed to a small percentage of the company's total revenue for the first nine months of 2025 [4] Group 4: R&D Investment - Yuandong Biological has maintained an average R&D investment of over 20% of its revenue in the past three years, leading to a high conversion efficiency with at least 10 new formulations approved for market each year [4]

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced its participation in the 11th national centralized drug procurement, with two products, Adrenaline Hydrochloride Injection and Beclomethasone Sodium Tablets, expected to be selected for procurement [1][2]. Group 1: Product Information - The two products proposed for selection are Adrenaline Hydrochloride Injection, which received its drug registration certificate in May 2022, and Beclomethasone Sodium Tablets, which received its certificate in May 2024 [2]. - Sales revenue for Beclomethasone Sodium Tablets from January to September 2025 was 1.2194 million, accounting for 0.12% of total revenue, while Adrenaline Hydrochloride Injection generated 21.7564 million, representing 2.13% of total revenue during the same period [2]. Group 2: Impact on Company - The centralized procurement is expected to prioritize the selected drugs in medical institutions, ensuring the completion of agreed procurement volumes. The selected products are anticipated to start execution in the first quarter of 2026, with no impact on the company's performance for the fiscal year 2025 [2]. - The selected procurement prices are expected to decrease compared to original sales prices, which may enhance drug accessibility [2]. Group 3: Company Strategy and R&D - The company has a diverse product matrix, with an average of over 20% of revenue invested in R&D over the past three years, leading to a high conversion rate of new products [3]. - The company has been actively increasing its portfolio of special narcotic drugs and expects new approved products to contribute to revenue growth. It is also accelerating its innovation transformation, focusing on core innovation pipelines such as molecular glue and PROTAC [3].

Core Viewpoint - Yuan Dong Bio (688513) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with two products, namely, Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets, expected to be selected for this procurement [1] Group 1 - The company participated in the centralized procurement bidding on October 27, 2025 [1] - The products involved in the bidding are Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with two products, namely, Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets, expected to be selected for this procurement [1] Group 1 - The company participated in the bidding for the 11th batch of national centralized drug procurement on October 27, 2025 [1] - The products involved in the procurement are Dexmedetomidine Hydrochloride Injection and Beraprost Sodium Tablets [1]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Core Viewpoint - Hainan Pharmaceutical's subsidiary Anhui Hengxing Pharmaceutical has received approval from the National Medical Products Administration for the "Dexamethasone Hydrochloride Injection" registration certificate, which is expected to positively impact the company's development and product line [1] Group 1 - The approved drug is used to treat clinical hypotension caused by vasodilation during anesthesia [1] - The drug is classified as a Category B product under the national medical insurance scheme [1] - The projected domestic hospital sales for Dexamethasone Hydrochloride Injection in 2024 is 119 million yuan [1] Group 2 - The approval will enrich the company's product line and optimize its product structure [1] - The development is seen as a positive influence on the company's growth trajectory [1]